Abstract
Introduction: Acute motor and sensory axonal neuropathy (AMSAN) is a variant of Guillain–Barré syndrome (GBS), characterized by acute paralysis and the loss of reflexes and sensory symptoms. The emerging evidence is growing to confirm that SARS‐CoV‐2 infection may be associated with neurological complications, including acute peripheral nerve diseases. Here we reported a case of AMSAN following the COVID-19 diagnosis.
Case presentation: A 59-year-old man with severe cold symptoms and the oral plague was diagnosed three weeks before the SARS-CoV-2 positive test results. Then the AMSAN disorder was confirmed after hospitalization and more laboratory, clinical, and electrophysiological investigations. However, interestingly, the patient revealed no respiratory symptom.
Conclusion: GBS can also occur in patients with COVID‐19 without respiratory symptoms. Since GBS syndrome can lead to patient mortality by involving the respiratory system, physicians should identify and treat early GBS and autonomic symptoms in coronavirus-affected individuals to prevent heart and respiratory failure. Accordingly, further studies on the early neurological symptoms of COVID‐19 and their consequences are recommended.
Keywords
Guillain-barre Syndrome COVID-19 Acute Motor and Sensory Axonal Neuropathy (AMSAN)
Fulltext
Full-text is available in PDF format.
Copyright
The Author(s) 2021. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.